The estimated Net Worth of Steven R Loranger is at least $13 millió dollars as of 16 November 2020. Mr. Loranger owns over 19,797 units of Edwards Lifesciences Corp stock worth over $3,205,361 and over the last 21 years he sold EW stock worth over $9,431,373. In addition, he makes $314,988 as Independent Director at Edwards Lifesciences Corp.
Sign up
Mr. Loranger EW stock SEC Form 4 insiders trading
Steven has made over 24 trades of the Edwards Lifesciences Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 19,797 units of EW stock worth $696,854 on 16 November 2020.
The largest trade he's ever made was exercising 165,690 units of Edwards Lifesciences Corp stock on 4 November 2015 worth over $3,086,805. On average, Steven trades about 14,098 units every 69 days since 2004. As of 16 November 2020 he still owns at least 46,965 units of Edwards Lifesciences Corp stock.
You can see the complete history of Mr. Loranger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Loranger biography
Steven R. Loranger is an Independent Director of the Edwards Lifesciences Corp. Mr. Loranger is a seasoned executive with global manufacturing and operational experience in highly regulated, high-tech industries. His decades of experience leading large, global innovation-focused corporations with intensive data privacy components is particularly valuable to our Board.
What is the salary of Steven Loranger?
As the Independent Director of Edwards Lifesciences Corp, the total compensation of Steven Loranger at Edwards Lifesciences Corp is $314,988. There are 14 executives at Edwards Lifesciences Corp getting paid more, with Michael Mussallem having the highest compensation of $11,521,000.
How old is Steven Loranger?
Steven Loranger is 68, he's been the Independent Director of Edwards Lifesciences Corp since 2016. There are 2 older and 18 younger executives at Edwards Lifesciences Corp. The oldest executive at Edwards Lifesciences Corp is William Link, 74, who is the Independent Director.
What's Steven Loranger's mailing address?
Steven's mailing address filed with the SEC is C/O XYLEM INC., 301 WATER STREET SE, WASHINGTON, DC, 20003.
Insiders trading at Edwards Lifesciences Corp
Over the last 21 years, insiders at Edwards Lifesciences Corp have traded over $94,964,396 worth of Edwards Lifesciences Corp stock and bought 47,398 units worth $3,992,090 . The most active insiders traders include Michael A Mussallem, Donald E Jr Bobo és Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of $1,126,057. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth $226,400.
What does Edwards Lifesciences Corp do?
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
What does Edwards Lifesciences Corp's logo look like?
Complete history of Mr. Loranger stock trades at Edwards Lifesciences Corp, Fedex Corp, ITT Inc, Textron és Xylem Inc
Edwards Lifesciences Corp executives and stock owners
Edwards Lifesciences Corp executives and other stock owners filed with the SEC include:
-
Michael Mussallem,
Chairman of the Board, Chief Executive Officer -
Scott Ullem,
Chief Financial Officer, Corporate Vice President -
Larry Wood,
Corporate Vice President - Transcatheter Aortic Valve Replacement -
Donald Bobo,
Corporate Vice President - Strategy and Corporate Development -
Catherine Szyman,
Corporate Vice President - Critical Care -
Jean-Luc Lemercier,
Corporate Vice President - EMEA (Europe, Middle East and Africa) -
Michael A. Mussallem,
Chairman & CEO -
Jean-Luc Lemercier,
Corp. VP of Europe, Middle East, Africa, Canada & Latin America -
Scott B. Ullem,
Corp. VP & CFO -
Larry L. Wood,
Corp. VP of Transcatheter Aortic Valve Replacement -
Donald E. Bobo Jr.,
Corp. VP of Strategy & Corp. Devel. -
Heisz Stone,
Independent Director -
William Link,
Independent Director -
Kieran Gallahue,
Independent Director -
Steven Loranger,
Independent Director -
Nicholas Valeriani,
Independent Director -
Martha Marsh,
Lead Independent Director -
Paul LaViolette,
Director -
Ramona Sequeira,
Director -
Daveen Chopra,
Corporate Vice President - Surgical Structural Heart -
Huimin Wang,
Corporate Vice President - Japan, Asia and Pacific -
Christine Z. McCauley,
Corp. VP of HR -
Dirksen J. Lehman,
Corp. VP of Public Affairs -
Arnold A. Pinkston,
Corp. VP & Gen. Counsel -
Mark Wilterding,
VP of Investor Relations -
Dr. Todd J. Brinton,
Corp. VP of Advanced Technology & Chief Scientific Officer -
Patrick B Verguet,
CVP, Europe -
John T Cardis,
Director -
Schack Wesley W Von,
Director -
Daniel J. Lippis,
CVP, JAPAC -
Carlyn D Solomon,
CVP, Critical Care & Vascular -
David E I Pyott,
Director -
Michael R Bowlin,
Director -
Bruce P Garren,
Corp VP, Gen Counsel & Secty -
Barbara J Mcneil,
Director -
Robert Alexander Ingram,
Director -
John H Jr Kehl,
Corp VP, Strategy & Bus Dev -
Thomas M Abate,
CVP, CFO and Treasurer -
Christine Z Mc Cauley,
CVP, Human Resources -
Robert C Reindl,
Corp VP, Human Resources -
Aimee S Weisner,
CVP, General Counsel -
Vernon R Jr Loucks,
Director -
Paul C Redmond,
CVP, CardioVations Surgcl Sys -
Corinne H Nevinny,
CVP, Chief Financial Officer -
Philip M Neal,
Director -
Stuart L Foster,
Corp VP, Technology/Discovery -
John Alexander Martin,
CVP, North America -
Anita Bessler,
Corp VP, Global Franchise Mgmt -
Randel William Woodgrift,
Corp VP, Manufacturing Ops -
J Randall Nelson,
Corp VP, North America -
David T Feinberg,
Director -
Robert W.A. Sellers,
SVP, Corporate Controller -
Bernard J Zovighian,
CEO -
Wayne Markowitz,
GM & SVP, Surgical -
Leslie C. Davis,
Director